The United States Patent and Trademark Office has announced a new COVID-19 Prioritized Examination Pilot Program.
Under this new program, the USPTO will grant requests for prioritized examination to up to 500 patent applications from applicants who qualify for small or micro entity status and will waive payment of the typical fees associated with other prioritized examination. In addition, the USPTO will endeavor to reach final disposition of applications in this program within six months if applicants respond promptly to communications.
To qualify for the new program, the claims of an application must cover a product or process that is subject to U.S. Food and Drug Administration (FDA) approval for use in the prevention and/or treatment of COVID-19. For more information on this pilot program, please see the statement on the USPTO website.
For more information about the USPTO Covid-19 response, visit the USPTO’s COVID-19 page.
Stay current on the latest COVID-19 IP News with email updates delivered straight to your inbox. Sign up now for daily alerts by filling out the form at the bottom of this window.
Reading this article on Lexology? Follow Harness Dickey for the latest updates.